| Project | Team | News & Events | References |
|---|
News & Events
It was a great experience to participate in the 5th Life Science Start-up Day, held this year in Göttingen. We are thrilled about this vibrant networking event offering numerous opportunities to connect with various pharmaceutical companies and to gain insights form young start-ups showcasting their ideas through elevator pitches. The interactive break-out session, ‘Startup Journey’, hosted by Life Science Factory, was highly informative and inspiring.
Prof. Thomas Thum joined recently the global Cardiovascular Clinical Trialists (CVCT) Forum in Washington DC and gave a talk within the session "What clinical trialsists can learn from biotech entrepreneurs". The session was attended by >100 specialists from pharma industry and university professors. Specifically, Prof. Thum also addressed the FIBREX project mentioning RNA therapeutics to combat cardiac remodelling.
As the biennial joint meeting of the ESC Working Groups on Cellular Biology of the Heart & Myocardial Function 2023 (CBFH) represents one of the most important events in the field of cardiovascular research, our FIBREX team was delighted to participate and contribute through oral and poster presentations. The impact of the non-coding genome on cardiovascular disease was the subject of excellent presentations and discussions by Prof. Thomas Thum and Prof. Christian Bär. Dr. Anne Bührke presented an exceptional poster emphasizing the significance of our FIBREX project and discussed the latest results with experts in the field.
In general, the meeting featured presentations and discussions on cutting-edge research, clinical trials, and therapeutic developments and brought together leading researchers, clinicians, and industry representatives to discuss the latest advances in the field of cardiac cellular biology and myocardial function. Furthermore, the attendance of pharmaceutical companies and biotech firms emphasized the significance of industry collaborations in promoting innovation and translating scientific discoveries into impactful clinical treatments. Thus, the conference served as a valuable opportunity for networking and collaboration between the scientific community and biotech firms in the cardiovascular research sector. Overall, this meeting served as an excellent platform for the dissemination of knowledge and enhancing the advancement of cardiovascular research.
Copyright Anne Bührke
IMTTS scientists Dr. Anne Bührke and Anita Pralas proudly represented our FIBREX Team at the ESGCT in Brussels. As the ESGCT is a leading organization in the field of gene and cell therapy, we were excited to join this prestigious event and contribute to the exchange of knowledge and advancements in this rapidly evolving field. The conference brought together experts from various fields of study and demonstrated the translation of innovative research into clinical applications. It included many inspiring talks and panel discussions, which led to an overall fascinating experience. Especially during the Symposium from the European Innovation Council (EIC) Cell and Gene Therapy community, we gained a lot of new insights and perspectives.
Copyright Anita Pralas
Prof. Thum recently visited the American Heart Associations meeting and met with many stakeholders from Industry to discuss the advent of RNA therapeutics including the FIBREX project.
We are excited to announce that we have participated at the annual conference of Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (DGK) in Mannheim. This prestigious event brought together leading experts, researchers, and professionals in the field of cardiology providing a platform for knowledge exchange, and discussion of the latest advancements and the most pressing issues in the field. The conference featured a diverse and engaging program including keynote lectures, panel discussions, and networking opportunities. IMTTS scientist Anita Pralas who is supporting the FIBREX Team presented the work of Dr. Anne Bührke in a poster session, which was nominated for the DGK poster award. Besides this, we had the opportunity to gain insight into current development pipelines of big pharma during several industry sponsored sessions, as well as to discuss their positions regarding the potential of non-coding RNA therapeutics for the treatment of CVD. Overall, our visit to the DGK 2023 in Mannheim was both enriching and rewarding.
Stay tuned for an update!
Stay tuned for an update!
Stay tuned for an update!
Stay tuned for an update!
Stay tuned for an update!
Stay tuned for an update!